EDITORIAL
Published on 22 May 2017
Editorial: Second Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological and Molecular Aspects of Novel Promising Drugs
doi 10.3389/fmed.2017.00063
- 1,633 views
- Frontiers in Medicine
- Pathology
- Research Topics
- Second Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological and Molecular Aspects of Novel Promising Drugs
Second Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological and Molecular Aspects of Novel Promising Drugs
14k
Total downloads
67k
Total views and downloads
Submit your idea
You will be redirected to our submission process.
Articles
REVIEW
Published on 05 Apr 2017
Second-line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of Dacomitinib
doi 10.3389/fmed.2017.00036
- 4,572 views
- 11 citations
REVIEW
Published on 28 Feb 2017
Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib
doi 10.3389/fmed.2017.00013
- 16,800 views
- 16 citations
MINI REVIEW
Published on 13 Feb 2017
Second-Line Treatment of NSCLC—The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms
doi 10.3389/fmed.2017.00009
- 4,936 views
- 13 citations
REVIEW
Published on 23 Jan 2017
Historical Evolution of Second-Line Therapy in Non-Small Cell Lung Cancer
doi 10.3389/fmed.2017.00004
- 7,445 views
- 38 citations
REVIEW
Published on 18 Jan 2017
Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line
doi 10.3389/fmed.2016.00076
- 27,232 views
- 104 citations
MINI REVIEW
Published on 23 Dec 2016
Liquid Biopsy in Non-Small Cell Lung Cancer
doi 10.3389/fmed.2016.00069
- 10,084 views
- 59 citations
REVIEW
Published on 19 Dec 2016
Focus on Nintedanib in NSCLC and Other Tumors
doi 10.3389/fmed.2016.00068
- 3,547 views
- 11 citations
REVIEW
Published on 13 Dec 2016
Focus on Nivolumab in NSCLC
doi 10.3389/fmed.2016.00067
- 5,511 views
- 8 citations
MINI REVIEW
Published on 30 Nov 2016
Focus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLC
doi 10.3389/fmed.2016.00065
- 5,931 views
- 9 citations
Published in
Frontiers in Medicine
- Pathology
Impact
- 67kTopic views
- 50kArticle views
- 14kArticle downloads